# US 2003/0229022 A1 · Pharmaceutical formulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0229022 A1
- Document ID: US20030229022A1
- Status: Published application
- Kind: A1
- Application number: 10/456,831
- Filed: 2003-06-06
- Published: 2003-12-11
- Earliest claimed: 2002-06-07
- Assignees: Abbott Laboratories
- Inventors: Fortuna Haviv; Bryan K. Erickson; Jack Henkin; Luk C. Li; Fanfeng Ma; Friedrich W. Richter; Yi Shi; Jingfeng Song; Siriporn Toongsuwan
- Web page: https://patentgrep.com/patent/US20030229022A1

## CPC

- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Parenteral formulations of peptides which are useful for sustained release are disclosed. Also disclosed are methods of preparation for the formulations.

## Claims

### Claim 1

A pharmaceutical composition comprising:
(a) a therapeutically effective amount of a compound of formula (I) R1-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Ile-Arg-Pro-Xaa10 (I), (SEQ ID NO:1); or a therapeutically acceptable salt thereof, wherein
R1 is CH3—C(O)—;
Xaa1 is absent or sarcosyl;
Xaa2 is absent or glycyl;
Xaa3 is absent or selected from the group consisting of glutaminyl and valyl;
Xaa4 is absent or selected from the group consisting of D-alloisoleucyl and D-isoleucyl;
Xaa5 is selected from the group consisting of seryl and threonyl;
Xaa6 is selected from the group consisting of glutaminyl, norvalyl, and seryl; and
xaa10 is selected from the group consisting of —NHCH2CH3 and D-alanylethylamide; provided that when Xaa4 is D-alloisoleucyl, Xaa1 is absent;
(b) poly(lactide-co-glycolide); and
(c) an organic solvent.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1 wherein the compound of formula (I) is selected from the group consisting of
N-Ac-Sar-Gly-Val-DIle-Thr-Nva-Ile-Arg-ProNHCH2CH3;
N-Ac-Sar-Gly-Val-DIle-Thr-Gln-Ile-Arg-ProNHCH2CH3;
N-Ac-DalloIle-Ser-Ser-Ile-Arg-ProNHCH2CH3; and
N-Ac-Gly-Val-DalloIle-Ser-Gln-Ile-Arg-ProNHCH2CH3.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1 wherein the compound of formula (I) is selected from the group consisting of
N-Ac-DalloIle-Thr-Ser-Ile-Arg-ProNHCH2CH3;
N-Ac-Thr-Gln-Ile-Arg-ProNHCH2CH3 (SEQ ID NO:2); and
N-Ac-Gly-Gln-DIle-Thr-Nva-Ile-Arg-Pro-DAlaNH2.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1 wherein the therapeutically acceptable salt is selected from the group consisting of acetate, pivalate, valproate, and octanoate.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1 which comprises between about 1% and about 15% (w/w) of the compound of formula (I), or a therapeutically acceptable salt thereof.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1 which comprises between about 3% and about 6% (w/w) of the compound of formula (I).

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1 which comprises between about 25% and about 45% (w/w) poly(lactide-co-glycolide).

### Claim 8 (depends on 7)

The pharmaceutical composition of claim 7 which comprises about 35% (w/w) poly(lactide-co-glycolide).

### Claim 9 (depends on 1)

The pharmaceutical composition of claim 1 wherein the poly(lactide-co-glycolide) has a weight of between about 6 and about 60 KD.

### Claim 10 (depends on 9)

The pharmaceutical composition of claim 9 wherein the poly(lactide-co-glycolide) has a weight of between about 13 and about 24 KD.

### Claim 11 (depends on 1)

The pharmaceutical composition of claim 1 wherein the organic solvent is N-methyl-2-pyrrolidinone.

### Claim 12 (depends on 1)

The pharmaceutical composition of claim 1 wherein the organic solvent is triacetin.

### Claim 13 (depends on 1)

The pharmaceutical composition of claim 1 wherein the organic solvent is a mixture of N-methyl-2-pyrrolidinone and triacetin.

### Claim 14 (depends on 13)

The pharmaceutical composition of claim 13 wherein the N-methyl-2-pyrrolidinone and the triacetin are in a weight ratio of from about 1:2 to about 6:1.

### Claim 15 (depends on 13)

The pharmaceutical composition of claim 13 wherein the N-methyl-2-pyrrolidinone and the triacetin are in a weight ratio of about 2:1.

### Claim 16 (depends on 13)

The pharmaceutical composition of claim 13 wherein the N-methyl-2-pyrrolidinone and the triacetin are in a weight ratio of about 1:1.

### Claim 17

A pharmaceutical composition comprising:
(a) about 3% to about 5% (w/w) of the compound of formula (Ia) N-Ac-Sar-Gly-Val-DIle-Thr-Nva-Ile-Arg-ProNHCH2CH3 (Ia), or a therapeutically acceptable salt thereof;
(b) about 35% (w/w) poly(lactide-co-glycolide); and
(c) about a 2:1 (w/w) mixture of N-methylpyrrolidinone and triacetin.

### Claim 18 (depends on 17)

The pharmaceutical composition of claim 17 wherein the therapeutically acceptable salt is selected from the group consisting of acetate, pivalate, valproate, and octanoate.

### Claim 19

A pharmaceutical composition comprising:
(a) about 3% (w/w) of the compound of formula (Ib) N-Ac-Sar-Gly-Val-DIle-Thr-Gln-Ile-Arg-ProNHCH2CH3 (Ib), or a therapeutically acceptable salt thereof;
(b) about 35% (w/w) poly(lactide-co-glycolide); and
(c) about a 1:1 (w/w) mixture of N-methylpyrrolidinone and triacetin.

### Claim 20 (depends on 19)

The pharmaceutical composition of claim 19 wherein the therapeutically acceptable salt is selected from the group consisting of acetate, pivalate, valproate, and octanoate.

### Claim 21

A pharmaceutical composition comprising:
(a) about 6% (w/w) of the compound of formula (Ib) N-Ac-Sar-Gly-Val-DIle-Thr-Gln-Ile-Arg-ProNHCH2CH3 (Ib), or a therapeutically acceptable salt thereof;
(b) about 33% (w/w) poly(lactide-co-glycolide); and
(c) about a 2:1 (w/w) mixture of N-methylpyrrolidinone and triacetin.

### Claim 22 (depends on 21)

The pharmaceutical composition of claim 21 wherein the therapeutically acceptable salt is selected from the group consisting of acetate, pivalate, valproate, and octanoate.

### Claim 23

A pharmaceutical composition comprising:
(a) about 3% (w/w) of the compound of formula (Ic) N-Ac-DalloIle-Ser-Ser-Ile-Arg-ProNHCH2CH3 (Ic), or a therapeutically acceptable salt thereof;
(b) about 34% (w/w) poly(lactide-co-glycolide); and
(c) about a 2:1 (w/w) mixture of N-methylpyrrolidinone and triacetin.

### Claim 24 (depends on 23)

The pharmaceutical composition of claim 23 wherein the therapeutically acceptable salt is selected from the group consisting of acetate, pivalate, valproate, and octanoate.

### Claim 25

A pharmaceutical composition comprising:
(a) about 3% (w/w) of the compound of formula (Id) N-Ac-Gly-Val-DalloIle-Ser-Gln-Ile-Arg-ProNHCH2CH3 (Id), or a therapeutically acceptable salt thereof;
(b) about 34% (w/w) poly(lactide-co-glycolide); and
(c) about a 2:1 (w/w) mixture of N-methylpyrrolidinone and triacetin.

### Claim 26 (depends on 25)

The pharmaceutical composition of claim 25 wherein the therapeutically acceptable salt is selected from the group consisting of acetate, pivalate, valproate, and octanoate.

### Claim 27

A method for preparing a pharmaceutical composition comprising:
(a) combining between about 25% and about 45% (w/w) poly(lactide-co-glycolide) and about 1% to about 15% (w/w) of a compound of formula (I), or a therapeutically acceptable salt thereof, in an organic solvent; and
(b) stirring the product of step (a).

### Claim 28

A method for preparing a pharmaceutical composition comprising:
(a) dissolving between about 25% and about 45% (w/w) poly(lactide-co-glycolide) in an organic solvent selected from the group consisting of N-methyl-2-pyrrolidinone, triacetin, 2-pyrrolidinone, and mixtures thereof;
(b) treating the product of step (a) with about 2% to about 10% (w/w) of a compound of formula (I), or a therapeutically acceptable salt thereof; and
(c) stirring the product of step (b).

### Claim 29 (depends on 28)

The method of claim 28 wherein the compound of formula (I) is selected from the group consisting of
N-Ac-Sar-Gly-Val-DIle-Thr-Nva-Ile-Arg-ProNHCH2CH3;
N-Ac-Sar-Gly-Val-DIle-Thr-Gln-Ile-Arg-ProNHCH2CH3;
N-Ac-DalloIle-Ser-Ser-Ile-Arg-ProNHCH2CH3; and
N-Ac-Gly-Val-DalloIle-Ser-Gln-Ile-Arg-ProNHCH2CH3.

### Claim 30 (depends on 28)

The method of claim 28 wherein the compound of formula (I) is selected from the group consisting of
N-Ac-DalloIle-Thr-Ser-Ile-Arg-ProNHCH2CH3;
N-Ac-Thr-Gln-Ile-Arg-ProNHCH2CH3 (SEQ ID NO:2);
N-Ac-Gly-Gln-DIle-Thr-Nva-Ile-Arg-Pro-DAlaNH2.

### Claim 31 (depends on 28)

The method of claim 28 wherein the therapeutically acceptable salt is selected from the group consisting of acetate, pivalate, valproate, and octanoate.

### Claim 32 (depends on 28)

The method of claim 28 wherein the pharmaceutical composition comprises between about 33% and about 35% (w/w) poly(lactide-co-glycolide).

### Claim 33 (depends on 28)

The method of claim 28 wherein the poly(lactide-co-glycolide) has a weight of between about 13 and about 24 KD.

### Claim 34 (depends on 28)

The method of claim 28 wherein the organic solvent is N-methyl-2-pyrrolidinone.

### Claim 35 (depends on 28)

The method of claim 28 wherein the organic solvent is triacetin.

### Claim 36 (depends on 28)

The method of claim 28 wherein the organic solvent is a mixture of N-methyl-2-pyrrolidinone and triacetin.

### Claim 37 (depends on 36)

The method of claim 36 wherein the N-methyl-2-pyrrolidinone and the triacetin are in a weight ratio of from about 1:2 to about 6:1.

### Claim 38 (depends on 36)

The method of claim 36 wherein the N-methyl-2-pyrrolidinone and the triacetin are in a weight ratio of from about 2:1 to about 1:1.

### Claim 39 (depends on 28)

The method of claim 28 wherein step (c) is conducted at about 20° C. to about 25° C.

### Claim 40

A method for preparing a pharmaceutical composition comprising:
(a) dissolving about 35% (w/w) 13 KD poly(lactide-co-glycolide) in about a 2:1 (w/w) mixture of N-methyl-2-pyrrolidinone and triacetin;
(b) treating the product of step (a) with about 3% to about 5% (w/w) of the compound of formula (Ia), or a therapeutically acceptable salt thereof; and
(c) stirring the product of step (b) at about 20° C. to about 25° C.

### Claim 41 (depends on 40)

The method of claim 40 wherein the therapeutically acceptable salt is selected from the group consisting of acetate, pivalate, valproate, and octanoate.

### Claim 42

A method for preparing a pharmaceutical composition comprising:
(a) dissolving about 35% (w/w) 13 KD poly(lactide-co-glycolide) in about a 1:1 (w/w) mixture of N-methyl-2-pyrrolidinone and triacetin;
(b) treating the product of step (a) with about 3% (w/w) of the compound of formula (Ib), or a therapeutically acceptable salt thereof; and
(c) stirring the product of step (b) at about 20° C. to about 25° C.

### Claim 43 (depends on 42)

The method of claim 42 wherein the therapeutically acceptable salt is selected from the group consisting of acetate, pivalate, valproate, and octanoate.

### Claim 44

A method for preparing a pharmaceutical composition comprising:
(a) dissolving about 33% (w/w) 13 KD poly(lactide-co-glycolide) in about a 2:1 (w/w) mixture of N-methyl-2-pyrrolidinone and triacetin;
(b) treating the product of step (a) with about 6% (w/w) of the compound of formula (Ib), or a therapeutically acceptable salt thereof; and
(c) stirring the product of step (b) at about 20° C. to about 25° C.

### Claim 45 (depends on 44)

The method of claim 44 wherein the therapeutically acceptable salt is selected from the group consisting of acetate, pivalate, valproate, and octanoate.

### Claim 46

A method for preparing a pharmaceutical composition comprising:
(a) dissolving about 34% (w/w) 13 KD poly(lactide-co-glycolide) in about a 2:1 (w/w) mixture of N-methyl-2-pyrrolidinone and triacetin;
(b) treating the product of step (a) with about 3% (w/w) of the compound of formula (Ic), or a therapeutically acceptable salt thereof; and
(c) stirring the product of step (b) at about 20° C. to about 25° C.

### Claim 47 (depends on 46)

The method of claim 46 wherein the therapeutically acceptable salt is selected from the group consisting of acetate, pivalate, valproate, and octanoate.

### Claim 48

A method for preparing a pharmaceutical composition comprising:
(a) dissolving about 34% (w/w) 13 KD poly(lactide-co-glycolide) in about a 2:1 (w/w) mixture of N-methyl-2-pyrrolidinone and triacetin;
(b) treating the product of step (a) with about 3% (w/w) of the compound of formula (Id), or a therapeutically acceptable salt thereof; and
(c) stirring the product of step (b) at about 20° C. to about 25° C.

### Claim 49 (depends on 48)

The method of claim 48 wherein the therapeutically acceptable salt is selected from the group consisting of acetate, pivalate, valproate, and octanoate.

### Claim 50

A method for providing sustained delivery of a peptide comprising administering to a subject a pharmaceutical composition comprising:
(a) about 1% to about 15% (w/w) of a compound of formula (I) R1-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Ile-Arg-Pro-Xaa10 (I), (SEQ ID NO:1); or a therapeutically acceptable salt thereof, wherein
R1 is CH3—C(O)—;
Xaa1 is absent or sarcosyl;
Xaa2 is absent or glycyl;
Xaa3 is absent or selected from the group consisting of glutaminyl and valyl;
Xaa4 is absent or selected from the group consisting of D-alloisoleucyl and D-isoleucyl;
Xaa5 is selected from the group consisting of seryl and threonyl;
Xaa6 is selected from the group consisting of glutaminyl, norvalyl, and seryl; and
Xaa10 is selected from the group consisting of —NHCH2CH3 and D-alanylethylamide; provided that when Xaa4 is D-alloisoleucyl, Xaa1 is absent;
(b) about 25% to about 45% (w/w) poly(lactide-co-glycolide); and
(c) an organic solvent selected from the group consisting of N-methyl-2-pyrrolidinone, triacetin, and mixtures thereof.

### Claim 51 (depends on 50)

The method of claim 50 wherein the compound of formula (I) is selected from the group consisting of
N-Ac-Sar-Gly-Val-DIle-Thr-Nva-Ile-Arg-ProNHCH2CH3;
N-Ac-Sar-Gly-Val-DIle-Thr-Gln-Ile-Arg-ProNHCH2CH3;
N-Ac-DalloIle-Ser-Ser-Ile-Arg-ProNHCH2CH3; and
N-Ac-Gly-Val-DalloIle-Ser-Gln-Ile-Arg-ProNHCH2CH3.

### Claim 52 (depends on 50)

The method of claim 50 wherein the compound of formula (I) is selected from the group consisting of
N-Ac-DalloIle-Thr-Ser-Ile-Arg-ProNHCH2CH3;
N-Ac-Thr-Gln-Ile-Arg-ProNHCH2CH3 (SEQ ID NO:2); and
N-Ac-Gly-Gln-DIle-Thr-Nva-Ile-Arg-Pro-DAlaNH2.

### Claim 53 (depends on 50)

The method of claim 50 wherein the therapeutically acceptable salt is selected from the group consisting of acetate, pivalate, valproate, and octanoate.
